Eisai announced results from a global study of nearly 1800 people with early-stage Alzheimer's. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after ...<br /><br />VIEW MORE : https://bit.ly/1breakingnews<br />
